Replies to post #80384 on Biotech Values

[DewDiligence]

This deal was a coup for JNJ—they exploited ELN’s dire financial condition to “steal” 25% of the Bapineuzumab program.

great deal for Elan, I wouldn't give 2 cents for Bap

??? Just because Bap is a longshot to succeed doesn’t mean it’s worth nothing. I’d like to play some backgammon with you for high stakes.